化合物详情

CAS3239-45-0

分子式C12H17ClF3N

分子量267.72 g/mol

非危品

Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.

科学粮草官-词典编辑部，修订于：2026-07-06

Toxicity

Symptoms

Symptoms of overdose include respiratory failure and cardiac arrest leading to death.

Treatment

General supportive measures for oral drug overdose should be instituted. Measures that have been used in dexfenfluramine overdose cases include aspiration of gastric contents, gastric lavage with activated charcoal, osmotic diuresis, forced acid diuresis, and careful monitoring of CNS or respiratory depression. The effectiveness of dialysis is not known. Patients should be followed closely until there is no further evidence of drug-related CNS effects. No specific therapy for dexfenfluramine overdose is known. (L1712)

Exposure Routes

Well-absorbed from the gastrointestinal tract.

Toxicity Summary

Dexfenfluramine binds to the serotonin reuptake pump. This causes inhbition of serotonin reuptake. The increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates.

Carcinogen Classification

No indication of carcinogenicity to humans (not listed by IARC).